Breaking News

Cytovance Adds Compliance Directors

August 12, 2014

Ambrose and Garstka bring extensive quality experience

Mark Ambrose, Ph.D., has been appointed senior director of Quality Systems and Compliance at Cytovance Biologics and Anne Garstka has been named director of Commercial Compliance. 
Dr. Ambrose has 20 years of quality experience and previously served as vice president of Quality at Nuron Biotech in Exton, PA, where he was responsible for quality leadership including GMP, GCP, GDP and GLP and the development and implementation of quality systems to support clinical and commercial products. He also served as the acting head of Regulatory Affairs.
Prior to Nuron Biotech, Dr. Ambrose served as Quality Operations product leader and director of sustainable compliance at Wyeth Biotech, now Pfizer. In these capacities, he was responsible for global product quality for Pfizer's Meningitec vaccine including formulation and implementation of life cycle product quality strategies.  
Ms. Garstka brings 15 years of quality and compliance management experience and previously served as director of Quality Assurance and Compliance for Neos Therapeutics, where she developed and implemented quality policies to ensure compliance and modified and maintained quality systems to meet changing industry guidelines. Ms. Garstka was also a Quality Assurance manager at Celgene Celluar Therapeutics, where she was responsible for developing and maintaining quality systems to meet industry requirements for a pharma development/clinical manufacturing center. 
"We are very fortunate to welcome such seasoned professionals to the Cytovance Quality team," said Maria Lopez, vice president of Quality for Cytovance Biologics. "Mark's experience with CMO/client relationships and Anne's experience in working side-by-side with internal and external customers will be tremendous assets to the Company. Their combined wealth of knowledge will allow Cytovance to expedite process and system improvements so that we can become even better partners with our clients."

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks